MJ_Prototype/iStock via Getty Images Digital and mobile healthcare platform in China, 111 Inc ( NASDAQ: YI ) on Tuesday announced that it has entered into a strategic direct supply partnership with Beijing Scrianen Pharmaceutical Co., a pharmaceutical enterprise that integrates research and development, production and marketing. The new agreement aims to enhance their existing collaboration, focusing on a range of products including "Scrianen Folic Acid Tablets" for nationwide distribution.
Since 2017, 111 ( YI ) became a strategic partner in Scrianen's Authentic Alliance. This latest Partnership deepens their retail market cooperation by leveraging big data, digital marketing, and cloud services to help Scrianen's medications and pregnancy-related products reach a broader online and offline market with added efficiency to broaden drug accessibility. Source: Press Release More on 111 111, Inc.
(YI) Q1 2024 Earnings Call Transcript 111, Inc. (YI) Q4 2023 Earnings Call Transcript Financial information for 111.